|
|
|
06.06.25 - 23:36
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective June 5th, 2025, to three non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 69,875 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”). The awards were granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $1.26 per share, which is equal to the closing price of Gossamer's common stock as reported by The Nasdaq Global Select Market...
|
|
|
|
|
|
|
12.05.25 - 22:03
|
Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025 (Business Wire)
|
|
|
SAN DIEGO--(BUSINESS WIRE)--$GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025.
In connection with the earnings release, Gossamer's management team will host a live conference call and webcast at 4:30 p.m. ET on Thursday, May 15, 2025, to discuss the Company's financial results and provide a corporate update.
Domestic Dial-in Number: (800) 285-6670
International Dial-in Number: (713) 481-0091
Live Webcast: https://edge.media-server.com/mmc/p/m5ahx8qm
A replay of the audio webcast will be available for 30 days on the Investors section of the Company's website, www.gossamerbio.com.
About Gossamer Bio
Gossamer Bio is a late-stage, clinical biopharmaceutical company f...
|
|
|
07.05.25 - 23:36
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
SAN DIEGO--(BUSINESS WIRE)--$GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 5, 2025, to three non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 258,750 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”). The awards were granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $1.25 per share, which is equal to the closing price of Gossamer's common stock as reported by The Nasdaq Global Select M...
|
|
|
08.04.25 - 23:33
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective April 7, 2025, to one non-executive employee of non-qualified stock option awards to purchase up to an aggregate of 55,000 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”). The awards were granted as an inducement material to the employee entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $0.82 per share, which is equal to the closing price of Gossamer's common stock as reported by The Nasdaq Global Select Market on A...
|
|
|
|
|
|
|
|
|
13.03.25 - 21:03
|
Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update (Business Wire)
|
|
|
- PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 -
- Registrational Phase 3 in PH-ILD Expected to Commence in Second Half of 2025 -
- Seralutinib Receives Orphan Drug Designation for PAH in Japan -
- Cash, cash equivalents and marketable securities totaled $295 million at year-end 2024 -
SAN DIEGO--(BUSINESS WIRE)--$GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided a business update.
“As we close the book on 2024 and embrace the promise of 2025, I am both humbled and energized by the remarkable progress that Gossamer has made in its mission to improve the lives of pulmonary hypertension patients,” said Faheem Hasnain, Chai...
|
|
|
07.03.25 - 23:36
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective March 5, 2025, to five non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 342,250 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”). The awards were granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $1.18 per share, which is equal to the closing price of Gossamer's common stock as reported by The Nasdaq Global Select Market ...
|
|
|
07.02.25 - 23:36
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective February 5, 2025, to three non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 510,000 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”). The awards were granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $1.15 per share, which is equal to the closing price of Gossamer's common stock as reported by The Nasdaq Global Select Market on...
|
|
|
07.01.25 - 23:33
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective January 6, 2025, to three non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 225,000 shares of the Company's common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan (“2023 Inducement Plan”). The awards were granted as an inducement material to the employees entering into employment with Gossamer in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $1.09 per share, which is equal to the closing price of Gossamer's common stock as reported by The Nasdaq Global Select Market on ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
